ADDF Statement on Topline Results from Phase 3 Trial of Amyloid-Clearing Drug Donanemab ...Middle East

PR Newswire - News
ADDF Statement on Topline Results from Phase 3 Trial of Amyloid-Clearing Drug Donanemab
Amyloid-targeting drugs make up one part of the biology of aging approach and are the first step in developing multiple drugs to treat Alzheimer's disease NEW YORK, May 3, 2023 /PRNewswire/ -- The Alzheimer's Drug Discovery Foundation (ADDF) is encouraged to see the positive data reported...

Read More Details
Finally We wish PressBee provided you with enough information of ( ADDF Statement on Topline Results from Phase 3 Trial of Amyloid-Clearing Drug Donanemab )

Apple Storegoogle play

Also on site :